Breaking Down Endo Health's Brilliant Buyout

From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment from Tuesday's episode, shares of Endo Health soared after the company announced it is buying the Canada-based Paladin Labs for $1.5 billion. Motley Fool health-care analyst David Williamson takes a close look at the deal and tells investors why the market reacted so favorably and whether he sees this as a good time to buy.

More Foolish insight
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Follow David on Twitter @MotleyDavid.

The article Breaking Down Endo Health's Brilliant Buyout originally appeared on

David Williamson has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story